(Serious Buyers Only) Leading Biotechnology Company For Sale | Probiotic | Postbiotic | Prebiotic

The company requires a larger strategic partner to scale operations and realize its full market potential.

An exceptional opportunity to acquire a fully operational, revenue-generating biotechnology company specializing in the research, development, and production of localized microbial strains. This company is a market leader of its category in the Singapore pet care sector and holds immense potential for expansion into human health and agriculture. The business is being offered as a full acquisition (with an option for the founder to retain a 20% minority stake and serve as a consultant) to ensure a seamless transition and continued growth.

Sub-industries that can be explored with this company
1. Beverage manufacturing (Cultured milk, canned drinks)
2. Beauty products manufacturing (Feminine care, Ezcema care and etc)
3. Agriculture products manufacturing (Treatment of sewage and etc)
4. Farm animal feeds manufacturing (Food for farm animals for human-consumption)
5. So much more than these

Key Value Proposition & Assets
This acquisition offers a "plug-and-play" biotech infrastructure with high barriers to entry due to proprietary IP and localized R&D.
Proprietary IP Portfolio: Ownership of 3 registered Trademarks and a library of more than 10 proprietary, localized strains (cannot be purchased anywhere else) of Lactobacillus motherseeds. These strains are specifically optimized for the Southeast Asian market and climate.
Award-Winning Product Range: A diverse catalog of high-margin formulas covering:
Pet Care: Market-leading supplements (Singapore’s top pet postbiotic brand).
Veterinary Care: Specialized clinical formulations. (Singapore's oldest pet probiotic brand).
Human Health: Probiotic, Postbiotic, and Prebiotic consumer goods.
Agriculture: Bio-solutions for crop and soil health.
Market Traction: Established brand equity in Singapore with a loyal customer base and proven sales channels.

Operational Capabilities
The company operates from a fully fitted, rented facility in Singapore. The acquisition includes the takeover of the facility lease, allowing the buyer to maintain immediate production continuity for the current group of clients.
Turnkey Manufacturing: The facility is equipped for the fermentation and production of localized strains.
Supply Chain: Established relationships with suppliers and distributors.

The Opportunity
The global probiotics market is projected to grow exponentially. This company is uniquely positioned to capture market share in the Asian pet and human wellness sectors.
Scalability: The existing formula library allows for rapid new product development (NPD).
Export Potential: While currently dominant in Singapore, the localized nature of the strains creates a competitive advantage for expansion into Malaysia, Indonesia, and the broader APAC region.

Proposed Transaction Structure
We are seeking a strategic buyer or investment group capable of scaling operations.
Structure: 80% Acquisition preferred.
Transition: Open to retaining a 20% equity stake and remaining onboard as a paid Consultant for a negotiated period to ensure R&D continuity, client retention, and operational stability.

Ideal Buyer Profile
Biotechnology firms looking to expand their strain library.
Pet care or nutraceutical companies seeking to vertically integrate manufacturing.
Investment groups looking for a high-growth, IP-rich asset in the biotech space.

Confidentiality
Financial details, specific strain data, and trademark registrations will be disclosed to serious, qualified buyers upon execution of a Non-Disclosure Agreement (NDA).